The failure of Roche’s onartuzumab (MetMab) in a targeted, Phase III advanced lung cancer study represents a blow to the company’s personalized oncology pipeline and raises questions about the future for drugs in the same class.
Roche subsidiary Genentech Inc. announced March 3 that in a planned interim analysis of the Phase III second-line/third-line MetLung...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?